OptimizeRx ( (OPRX) ) has provided an update.
On April 18, 2025, OptimizeRx Corporation announced its plan to appoint a new independent director to its board in the second half of 2025, as part of its ongoing efforts to refresh and expand its board of directors. This decision follows constructive engagement with Whetstone Capital Advisors, which withdrew its notice to nominate director candidates for the company’s 2025 Annual Meeting. The addition of a new director aims to enhance the board’s expertise and support the company’s strategy to build market share and drive revenue growth under the leadership of new CEO Steve Silvestro.
Spark’s Take on OPRX Stock
According to Spark, TipRanks’ AI Analyst, OPRX is a Outperform.
OptimizeRx’s stock is buoyed by strong technical indicators and a positive earnings outlook. However, financial performance is hindered by operational losses, and valuation remains a concern due to negative profitability metrics. The appointment of a new CEO is a promising strategic move, aligning with the company’s growth objectives.
To see Spark’s full report on OPRX stock, click here.
More about OptimizeRx
OptimizeRx is a leading healthcare technology company that redefines how life science brands connect with patients and healthcare providers. The company offers AI-driven tools like the Dynamic Audience Activation Platform and Micro-Neighborhood Targeting to deliver timely and relevant engagement. Headquartered in Waltham, Massachusetts, OptimizeRx partners with pharmaceutical and life sciences companies to transform the healthcare landscape.
YTD Price Performance: 62.19%
Average Trading Volume: 516,590
Technical Sentiment Signal: Buy
Current Market Cap: $151.3M
See more data about OPRX stock on TipRanks’ Stock Analysis page.